Bone Abmormalities and Healing Defect in Muscular Dystrophy

Information

  • Research Project
  • 9917937
  • ApplicationId
    9917937
  • Core Project Number
    R01AR065445
  • Full Project Number
    7R01AR065445-07
  • Serial Number
    065445
  • FOA Number
    PA-18-590
  • Sub Project Id
  • Project Start Date
    4/30/2019 - 6 years ago
  • Project End Date
    4/30/2020 - 5 years ago
  • Program Officer Name
    CHEEVER, THOMAS
  • Budget Start Date
    6/1/2019 - 6 years ago
  • Budget End Date
    4/30/2020 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    07
  • Suffix
  • Award Notice Date
    7/18/2019 - 6 years ago

Bone Abmormalities and Healing Defect in Muscular Dystrophy

DESCRIPTION (provided by applicant): Duchenne Muscular Dystrophy (DMD) is a degenerative muscle disorder characterized by a lack of dystrophin expression that ultimately results in cardiac or respiratory failure. DMD patients also acquire osteopenia, fragility fracture, and scoliosis indicating that a deficiency in skeletal system homeostasis also occurs in DMD patients. It is speculated that these skeletal abnormalities are likely a secondary consequence to muscle loss (sarcopenia); however, it remains unclear if they could be due to a direct intrinsic skeletal defect. Recent evidence has emerged implicating adult stem cell dysfunction in the histopathogenesis of DMD. Muscle derived progenitor cells (MPCs) isolated from dystrophin/utrophin double knock-out (dKO) mice (a severe animal model of DMD) have been found to be defective in their proliferation and differentiation capacities. We, and others, have reported that these dKO mice exhibit a spectrum of degenerative changes in their bone, articular cartilage, and intervertebral discs and experience spinal deformities, heterotopic ossification, cardiomyopathy and a decreased lifespan, all of which support a premature musculoskeletal aging phenotype in this mouse model. A defect in bone healing was also observed in these mice; however, it is still unclear whether this defect is an intrinsic bone healing problem or associated with the secondary effects of sarcopenia (Aim 1). Preliminary evidence supports the existence of an adult stem cell defect in both MPCs and mesenchymal stem cells (MSCs) in these mice, supporting the theory that abnormal bone healing could be the consequence of an autonomous defect in the adult stem cell compartment. Thus the second aim of this project will be to further validate whether the MPCs and MSCs in these mice, analyzed at different ages, are defective in their proliferation and osteogenic differentiation capacities compared to MPCs and MSCs isolated from mdx and wild type (WT) mice. It has recently been shown that reducing fibroblast growth factor-2 (FGF2) activity prevents stem cell depletion/exhaustion; therefore, we also propose to determine whether FGF2 inhibitor-loaded biomimetic coacervate could rescue this autonomous adult stem cell defect and delay the onset of bone related histopathologies in dKO mice (Aim 2). Since there is also evidence that the stem cell niche may also negatively impact adult stem cell function, via a non-autonomous mechanism, we propose experiments to determine if the bone defect observed in dKO mice can be rescued through parabiotic pairing which will rejuvenate the dystrophic microenvironment by creating a shared circulation between a dKO and a young WT animal (Aim 3). We have preliminary data that supports the fact that circulating factors from young animals have a beneficial effect on the bone morphologies and healing capacity of dKO mice. In summary, this innovative grant application will: 1) determine whether the bone abnormalities and healing in dKO mice represent an intrinsic bone defect and 2) characterize whether the progressive bone histopathology observed in the dKO mice, is primarily driven by cell autonomous and/or non-autonomous mechanisms.

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R01
  • Administering IC
    AR
  • Application Type
    7
  • Direct Cost Amount
    316800
  • Indirect Cost Amount
    22000
  • Total Cost
    338800
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    846
  • Ed Inst. Type
  • Funding ICs
    NIAMS:338800\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    MTE
  • Study Section Name
    Musculoskeletal Tissue Engineering Study Section
  • Organization Name
    STEADMAN PHILIPPON RESEARCH INSTITUTE
  • Organization Department
  • Organization DUNS
    966298262
  • Organization City
    VAIL
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    816575242
  • Organization District
    UNITED STATES